Hodgkin's Lymphoma News

CancerConsultants provides summaries of new treatment strategies as they are discovered and reported by cancer physicians around the world. Our medical staff attends medical meetings worldwide and reviews medical literature daily to ensure appropriate news is provided to cancer patients and their families in a timely manner.

News of the results of recent clinical trials evaluating cancer therapies and supportive care strategies serve to educate patients regarding new treatment strategies for cancer and facilitate discussions with their doctor. Development of new cancer treatments usually begins in patients with recurrent or metastatic cancers. Once the new treatment appears effective, it is applied to earlier stages of the disease or to patients at higher risk of treatment failure.

Share

Hodgkin's Lymphoma News


Progress Reported in New Treatments for People with Lymphoma (December 29, 2016)

Research and pharmaceutical executives unveil encouraging clinical trial data at the annual meeting of the American Society of Hematology. Twenty-two years ago, Dr. Gary Gordon, Ph.D., vice president of... Continue Reading

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published... Continue Reading

Patients Rising: Voices of Value (September 1, 2016)

By Terry Wilcox When Jennifer Hinkel was diagnosed with Hodgkin’s lym­phoma in 1998 at the age of 17, her life as she knew it came to a standstill: from her daily routine to her long-term plans, her... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant (March 30, 2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio... Continue Reading

Crafting a Better T Cell for Immunotherapy (February 25, 2016)

New technology, not yet tested in humans, aims to reduce patients’ waiting time, increase potency of T-cell therapy T-cell therapy, a form of immunotherapy that uses a patient’s own immune cells to... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood... Continue Reading

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma (October 6, 2015)

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma.... Continue Reading

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma (May 7, 2015)

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with  Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these... Continue Reading

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 23, 2014)

CancerConnect News: The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according... Continue Reading

More Hodgkin's Lymphoma News

Latest Hodgkin's Lymphoma News By Stage


Early Stage

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care (December 12, 2014)

CancerConnect News– The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL) according to the results of a clinical trail presented... Continue Reading

Radiation Therapy Improves 10-Year Survival for Patients With Early Hodgkin’s Lymphoma (October 30, 2014)

According to a large observational study based on the National Cancer Database (NCDB), adding consolidation radiation therapy to chemotherapy significantly improves 10-year survival in patients with stage I and II Hodgkin’s lymphoma (HL).  The findings... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood cancers into focus, it’s time to increase public... Continue Reading

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (February 26, 2014)

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal of Clinical Oncology. Most patients relapsed, but... Continue Reading

More Early Stage

Advanced Stage

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 23, 2014)

CancerConnect News: The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers at the American Society of... Continue Reading

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 18, 2014)

CancerConnect News:The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher recently published in The New... Continue Reading

Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care (December 12, 2014)

CancerConnect News– The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL) according to the results of a clinical trail presented... Continue Reading

More Advanced Stage

Progressive Relapsed

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma (October 6, 2015)

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma. These results were recently published in the... Continue Reading

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma (May 7, 2015)

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with  Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these findings online. Hodgkin’s lymphoma is a cancer... Continue Reading

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 23, 2014)

CancerConnect News: The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers at the American Society of... Continue Reading

More Progressive Relapsed

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS